Kodiak Sciences Inc. $KOD Shares Bought by Baker BROS. Advisors LP

Baker BROS. Advisors LP grew its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 15.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 19,919,186 shares of the company’s stock after purchasing an additional 2,608,696 shares during the quarter. Kodiak Sciences accounts for about 3.3% of Baker BROS. Advisors LP’s holdings, making the stock its 11th biggest holding. Baker BROS. Advisors LP owned 0.38% of Kodiak Sciences worth $556,940,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC boosted its holdings in shares of Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at $29,000. Headlands Technologies LLC boosted its holdings in shares of Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after acquiring an additional 5,815 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at $72,000. Finally, Strs Ohio acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at $87,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Stock Up 8.4%

KOD stock opened at $35.71 on Thursday. The company has a market capitalization of $2.23 billion, a P/E ratio of -8.56 and a beta of 2.21. The company has a 50-day simple moving average of $38.95 and a 200 day simple moving average of $30.89. Kodiak Sciences Inc. has a fifty-two week low of $3.43 and a fifty-two week high of $47.84.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.01). Equities analysts anticipate that Kodiak Sciences Inc. will post -3.89 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on KOD. HC Wainwright reissued a “buy” rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a report on Friday, March 27th. UBS Group upped their price objective on shares of Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 27th. Chardan Capital raised shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $14.00 to $61.00 in a report on Monday, May 11th. Finally, Wall Street Zen raised shares of Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.14.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.